Cite
HARVARD Citation
Vermersch, P. et al. (2022). Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial. European journal of neurology. pp. 790-801. [Online].